Drug Overview

AKT inhibitor LY2780301 is an advanced, experimental cancer medication. In the medical field, it is classified as a “Targeted Therapy” or a “Smart Drug.” Unlike older chemotherapy treatments that attack all fast-growing cells in the entire body, targeted therapies are specially designed to find and block specific broken signals inside cancer cells.

Currently, LY2780301 is an investigational drug. This means it is not yet available at your local pharmacy and does not have a commercial brand name. It is actively being studied in clinical trials at major research hospitals. Doctors are testing how well it fights certain solid tumors, especially advanced breast cancer, when combined with other treatments.

Generic Name: AKT inhibitor LY2780301 (often referred to simply as LY2780301)
US Brand Names: None (Currently an investigational drug)
Drug Class: Dual AKT and p70S6K Inhibitor / Targeted Therapy / Small Molecule Inhibitor
Route of Administration: Oral (Capsule)
FDA Approval Status: Not FDA Approved. It is actively being evaluated in Phase I and Phase II clinical trials.

What Is It and How Does It Work? (Mechanism of Action)

To understand how LY2780301 works, we need to look inside the cells at the molecular level.

Inside human cells, there is a complex communication network known as the PI3K/AKT/mTOR signaling pathway. Think of this pathway as a set of traffic lights that tells the cell when to grow, divide, and survive. In many types of cancer, these traffic lights are broken and permanently stuck on “green.” This causes the cancer cells to multiply out of control and refuse to die when they normally should.

LY2780301 is a dual-action inhibitor. This means it acts like a precise molecular wrench that tightens two specific bolts to turn the traffic light red:

AKT (Protein Kinase B): This is the main protein keeping the growth signal turned on. The drug binds directly to AKT and blocks it from working.
p70S6K: This is another protein further down the chain that helps the cancer cell build proteins to grow. The drug also blocks this secondary target.

By shutting down both AKT and p70S6K, the drug successfully cuts the main power lines inside the cell. Without the constant signal to grow and survive, the cancer cells stop dividing and trigger a natural process called apoptosis (programmed cell death).

FDA Approved Clinical Indications

Important Note: Because LY2780301 is an experimental medication, it does not currently have official FDA approvals for general public use. However, it is being actively tested in clinical trials for the following investigational oncological uses:

Treatment of HER2-negative locally advanced or metastatic breast cancer (often combined with the chemotherapy drug paclitaxel).
Treatment of advanced solid tumors that have genetic mutations in the PI3K/AKT pathway (often combined with the drug gemcitabine).
Treatment of certain advanced Non-Hodgkin’s Lymphomas.

Non-oncological uses:

None. This drug is strictly being studied for cancer treatment.

Dosage and Administration Protocols

Because LY2780301 is an investigational drug, the exact dosage is decided by strict clinical trial rules. The table below outlines the general dosing protocols used in major clinical studies (such as the TAKTIC and INPAKT trials).

Patient Age/Type	Route of Administration	Standard Trial Dose	Frequency	Infusion Time
Adults (Clinical Trial)	Oral	400 mg to 500 mg	Once daily	Not Applicable (Swallowed as a pill)

Dose Adjustments

Renal Insufficiency (Kidney Issues): Patients must have adequate kidney function to enter the trial. Severe kidney issues may require dose lowering or exclusion from the trial.
Hepatic Insufficiency (Liver Issues): The drug is processed by the liver. In trials, patients with mild liver issues are monitored closely. If liver enzyme blood tests become too high during treatment, the trial doctor will either lower the daily dose (for example, down to 300 mg) or temporarily stop the drug until the liver recovers.

Clinical Efficacy and Research Results

Recent clinical research between 2020 and 2025 has provided very encouraging data, particularly for breast cancer patients.

Breast Cancer Survival: In the TAKTIC Phase IB/II trial (results published in late 2021 and 2022), LY2780301 was given alongside weekly paclitaxel chemotherapy to patients with HER2-negative metastatic breast cancer. The results showed an Overall Response Rate (ORR) of nearly 63%, meaning the tumors shrank significantly in the majority of patients.
Disease Progression: In the same breast cancer study, the median Progression-Free Survival (the amount of time the cancer was stopped from growing) was approximately 12.4 months, which is considered highly promising for metastatic disease. The 6-month clinical benefit rate was almost 83%.
Predictive Biomarkers: A 2022 study showed that doctors can use a simple blood test to look for “circulating tumor DNA” (ctDNA) before treatment begins. Patients whose blood showed lower levels of this mutated DNA had even better survival rates and longer disease control on LY2780301.

Safety Profile and Side Effects

Because targeted therapies block specific pathways that healthy cells also sometimes use, they come with a unique set of side effects compared to traditional chemotherapy.

No Black Box Warning

There is no FDA Black Box Warning for LY2780301, as it is still in the investigational phase.

Common Side Effects (Occur in >10% of patients)

Skin Rash: Red, itchy breakouts on the skin are very common (affecting up to 90% of patients in some trials, mostly mild).
Fatigue and Weakness: Feeling unusually tired.
Gastrointestinal Issues: Nausea, vomiting, and diarrhea.
Anemia: Low red blood cell counts, causing tiredness.
Liver Enzyme Elevation: Mild changes in blood tests showing liver stress.

Serious Adverse Events (Occur rarely)

Severe Thrombocytopenia: Dangerously low blood platelets, which can increase the risk of heavy bleeding.
Pneumonia: Severe lung infections were seen in some trial combinations.

Side Effect Management Strategies

For Skin Rashes: Doctors often recommend alcohol-free, thick moisturizing creams and may prescribe mild steroid creams. Avoid hot showers and heavy sun exposure.
For Nausea and Diarrhea: Keep over-the-counter anti-diarrhea and anti-nausea medicines at home. Drink plenty of clear fluids to avoid dehydration.
For Low Blood Counts: Doctors will perform weekly blood tests to check your platelets and red blood cells to ensure they are at safe levels.

Research Areas

LY2780301 is a major focus in the research area of precision medicine and circulating tumor DNA (ctDNA). Scientists are actively testing how to use regular blood draws (liquid biopsies) to monitor the exact amount of cancer DNA floating in a patient’s blood while they take LY2780301. By tracking this DNA, doctors hope to predict exactly when a tumor might become resistant to the drug, allowing them to switch treatments before the cancer has a chance to physically grow. There is currently no significant research linking this drug to stem cell therapies or regenerative medicine.

Patient Management and Practical Recommendations

Pre-Treatment Tests to be Performed

Tumor Genetic Testing: A biopsy is often performed to see if the tumor carries specific PI3K or AKT mutations, helping doctors know if the drug will work best for you.
Liver and Kidney Panels: Blood tests to ensure your major organs are healthy enough for an experimental drug.
Complete Blood Count (CBC): To establish a baseline for your red blood cells, white blood cells, and platelets.

Precautions During Treatment

Infection Risk: Because the drug can lower blood cell counts, you may be at a slightly higher risk for infections like pneumonia. Wash hands frequently and avoid large crowds if possible.

Do’s and Don’ts

DO ask your oncologist if you qualify for an AKT-inhibitor clinical trial if you have advanced breast cancer or solid tumors.
DO swallow the capsules whole with a full glass of water. Do not crush, chew, or open the capsules.
DO use strong sun protection (SPF 30 or higher and a hat) when outside, as the drug can make your skin sensitive and prone to rashes.
DON’T start taking any new vitamins, herbal supplements (like St. John’s Wort), or over-the-counter medicines without telling your clinical trial team.
DON’T ignore signs of an infection, such as a high fever, severe cough, or shortness of breath. Contact your care team immediately if these occur.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. It should not be used to diagnose, treat, cure, or prevent any disease or health condition. Always consult with a qualified healthcare professional or your treating oncologist regarding specific medical concerns, clinical trial eligibility, treatment options, or before starting, stopping, or altering any medication regimen. Every patient’s medical situation is unique, and therapies should be customized by a licensed physician.